An interventional study of Choose Your Own Adventure App in Major Depressive Disorder, Depression and Adolescent Depression, sponsored by University of Minnesota. Not yet recruiting at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 703rd largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 6 that started in 2027, is one of 472 with no phase, reaches primary completion later than 225 of the 258 other live ones, and was the 1,495th registered.
3,046 studies on the registry are indexed under Depressive Disorder, Major; 592 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 412 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 293 (71%) stop at 75 or younger; 55 take children under 18; 98 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 6 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 2,532 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
University of Minnesota is the lead sponsor of 1,217 studies on the registry; 197 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
University of Minnesota has 5 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will develop and test Choose Your Own Adventure, a personalized app-based intervention designed to help adolescents with depression regulate social media use.
Adolescents ages 13 to 17 years with major depressive disorder and daily TikTok use will be randomized to either the CYOA app intervention or no intervention. The CYOA app is designed to detect individualized patterns of problematic social media use and offer personalized options to disrupt "runaway train" social media use.
The study will assess feasibility, acceptability, preliminary effects on social media use and mood, and potential mechanisms including social media self-control failure. Participants will complete baseline, post-intervention, and 3-month follow-up assessments.
Choose Your Own Adventure is a pilot randomized controlled clinical trial testing a personalized app-based intervention to regulate social media use in adolescents with depression.
The study will enroll 60 adolescents ages 13 to 17 years with major depressive disorder. Participants will be randomized 1:1 to the CYOA app intervention or no intervention. The intervention is designed to promote adolescent agency rather than force discontinuation of social media use. Adolescents assigned to CYOA will identify situations that may be harmful to their well-being and select preferred options for what to do when those situations arise.
The app will sense and characterize social media content and engagement patterns. When it detects a predefined "runaway train" social media use pattern, it will offer personalized options based on the adolescent's plan. Options may include pausing after a specified time or number of videos, modifying sensory intensity, engaging in a mindfulness activity, or editing the feed to remove topics the adolescent identifies as problematic.
Participants in both groups will download the study app and use it for 2 weeks. Adolescents will complete ecological momentary assessment prompts twice daily during the 2-week period. Baseline, post-intervention, and 3-month follow-up assessments will evaluate depression symptoms, anxiety, well-being, social connectedness, sleep, physical activity, social media self-control failure, and social media use patterns.
The main goals are to assess feasibility, acceptability, preliminary impact, and potential mechanisms of the CYOA intervention compared with no intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adolescents randomized to this arm will use the CYOA app for 2 weeks. The app is designed to detect individualized social media use patterns and offer personalized options to disrupt problematic "runaway train" social media use.
Behavioral: Choose Your Own Adventure App
Adolescents randomized to this arm will use social media as much or as little as preferred during the 2-week study period. They will still use the study app for data collection and complete the same study assessments as the intervention group.
The CYOA app is a personalized social media self-regulation intervention for adolescents with depression. Adolescents identify social media situations that may be harmful to their well-being and select preferred options for responding when those situations arise. When the app detects a "runaway train" social media use pattern based on predefined thresholds, it offers personalized options such as pausing use, modifying sensory intensity, engaging in mindfulness, or editing the feed to remove problematic content.
Also known as: CYOA App
CYOA App Use During Intervention Period
Feasibility will be assessed by the number and proportion of days, out of 14 days, that adolescents assigned to the CYOA app use the intervention. The feasibility target is use of the app on at least 8 of 14 days.
Time frame: During the 2-week intervention period
Acceptability of the CYOA App
Acceptability will be assessed using adapted Treatment Acceptability/Adherence Scale ratings with adolescents assigned to CYOA. Total score ranges from 9 to 63; higher scores indicate greater treatment acceptability/adherence. Create a separate outcome for qualitative interviews only if they are intended to be reported as an outcome, with a defined reporting measure.
Time frame: Post-intervention visit, after the 2-week intervention period
Social Media Use Patterns
Social media use patterns will be assessed using data extracted by the study app, including engagement patterns and app-based social media use data, and by self-report using the Social Media Use Scale. Social media use will be assessed using the Social Media Use Scale (SMUS). Total scores range from 17 to 153; higher scores indicate worse outcomes." Move app-derived engagement patterns into separate outcome entries once their specific measures are defined.
Time frame: During the 2-week intervention period
Daily Mood
Daily mood will be assessed using ecological momentary assessment prompts with items from the Positive and Negative Affect Schedule short form.
Time frame: Twice daily during the 2-week intervention period
Sleep
Sleep will be assessed using the Pittsburgh Sleep Quality Index at study visits and daily ecological momentary assessment of hours slept during the 2-week intervention period. Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 to 21; higher scores indicate worse sleep quality." Separate daily EMA hours slept.
Time frame: Baseline, post-intervention after 2 weeks, and 3-month follow-up; daily during the 2-week intervention period
Physical Activity
Physical activity will be assessed using the Moderate to Vigorous Physical Activity screening measure and daily ecological momentary assessment of minutes of physical activity. Physical activity will be assessed using the Moderate to Vigorous Physical Activity (MVPA) screening measure. Scores range from 0 to 7; higher scores indicate better outcomes.
Time frame: Baseline, post-intervention after 2 weeks, and 3-month follow-up; daily during the 2-week intervention period
Number of In-Person Social Interactions
The number of meaningful in-person social interactions will be assessed using daily ecological momentary assessment (EMA) questions during the intervention period.
Time frame: Daily during the 2-week intervention period.
Duration of In-Person Social Interactions
The duration of meaningful in-person social interactions will be assessed using daily ecological momentary assessment (EMA) questions during the intervention period.
Time frame: Daily during the 2-week intervention period.
Anxiety Symptoms
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 scale.Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7). Total scores range from 0 to 21; higher scores indicate greater anxiety symptom severity.
Time frame: Daily during the 2-week intervention period.
Well-Being as Measured by the Flourishing Scale
Well-being will be assessed using the Flourishing Scale (FS). Total scores range from 8 to 56, with higher scores indicating greater well-being.
Time frame: Baseline, post-intervention at 2 weeks, and 3-month follow-up
Well-Being as Measured by the Satisfaction with Life Scale
Well-being will be assessed using the Satisfaction with Life Scale (SWLS). Total scores range from 5 to 35, with higher scores indicating greater life satisfaction.
Time frame: Baseline, post-intervention at 2 weeks, and 3-month follow-up
Social Connectedness
Social connectedness will be assessed using the Social Connectedness Scale-Revised. Social connectedness will be assessed using the Social Connectedness Scale-Revised (SCS-R). Scores range from 0 to 6; higher scores indicate greater social connectedness
Time frame: Baseline, post-intervention after 2 weeks, and 3-month follow-up
Depression Symptoms - CDI-2 Child-Report
Depression symptoms will be assessed using the Children's Depression Inventory-2 (CDI-2), Child-Report. Scores range from 0 to 56; higher scores indicate greater depressive symptom severity.
Time frame: Baseline, post-intervention at 2 weeks, and 3-month follow-up
Depression Symptoms - CDI-2 Parent-Report
Depression symptoms will be assessed using the Children's Depression Inventory-2 (CDI-2), Parent-Report. Scores range from 0 to 51; higher scores indicate greater depressive symptom severity.
Time frame: Baseline, post-intervention at 2 weeks, and 3-month follow-up
Change in Social Media Self-Control Failure
Social media self-control failure will be assessed using the Social Media Self Control Failure scale. The study will evaluate whether CYOA is associated with greater decreases in social media self-control failure compared with no intervention. Social media self-control failure will be assessed using the Social Media Self Control Failure (SMSCF) Scale. Scores range from 3 to 15; higher scores indicate worse self-control failure.
Time frame: Baseline, post-intervention after 2 weeks, and 3-month follow-up
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Oct 2029, 28 months later.
Of 648 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 55. This study's planned 28 months is below that.
Counting every sponsor, half of 688 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.